ONC: BeiGene Ltd. American Depositary Shares Stocks News on November 16, 2025

Are Shares of BeOne Medicines Attractively Priced After Recent Cancer Therapeutics Collaboration?

ONC

Simply Wall St.

2 days ago

Are Shares of BeOne Medicines Attractively Priced After Recent Cancer Therapeutics Collaboration?

US Stock Market Today: S&P 500 Futures Rise as Shutdown Ends, Rate Jitters Build

ONC

Simply Wall St.

3 days ago

US Stock Market Today: S&P 500 Futures Rise as Shutdown Ends, Rate Jitters Build

Stock Market Today: Dow Hits New Highs; Lilly, Barrick, Goldman Break Out (Live Coverage)

ONC

Investor's Business Daily

4 days ago

Stock Market Today: Dow Hits New Highs; Lilly, Barrick, Goldman Break Out (Live Coverage)

BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie

ONC

Investor's Business Daily

4 days ago

BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie

BeOne Medicines Stock Earns Relative Strength Rating Upgrade

ONC

Investor's Business Daily

4 days ago

BeOne Medicines Stock Earns Relative Strength Rating Upgrade

ONC

MT Newswires

4 days ago

Asian Equities Traded in the US as American Depositary Receipts Advance in Wednesday Trading

Biotech Leader BeOne Medicines Eyes New Buy Point As Cancer Drug Sales Surge

ONC

Investor's Business Daily

5 days ago

Biotech Leader BeOne Medicines Eyes New Buy Point As Cancer Drug Sales Surge

BeOne Medicines Ltd (ONC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ...

ONC

GuruFocus.com

6 days ago

BeOne Medicines Ltd (ONC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ...

How Strong BRUKINSA Sales and Patent Resolution at BeOne Medicines (ONC) Have Changed Its Investment Story

ONC

Simply Wall St.

8 days ago

How Strong BRUKINSA Sales and Patent Resolution at BeOne Medicines (ONC) Have Changed Its Investment Story

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

ONC

Zacks

10 days ago

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

ONC

Business Wire

10 days ago

BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

BeOne Medicines to Present at Upcoming Investor Conferences

ONC

Business Wire

19 days ago

BeOne Medicines to Present at Upcoming Investor Conferences

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

ONC

Business Wire

25 days ago

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

ONC

Business Wire

a month ago

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment

ONC

Investor's Business Daily

a month ago

How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment

BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts

ONC

Insider Monkey

a month ago

BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts

Here’s Why BeOne Medicines Ltd. (ONC) Declined in Q2

ONC

Insider Monkey

2 months ago

Here’s Why BeOne Medicines Ltd. (ONC) Declined in Q2

BeOne Medicines AG (NASDAQ:ONC) About To Shift From Loss To Profit

ONC

Simply Wall St.

2 months ago

BeOne Medicines AG (NASDAQ:ONC) About To Shift From Loss To Profit

China’s Young Consumers Set the Global Trend. What They’re Buying Now.

ONC

Barrons.com

2 months ago

China’s Young Consumers Set the Global Trend. What They’re Buying Now.

Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC)

ONC

Insider Monkey

2 months ago

Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC)

Hims & Hers Leads 15 Growth Stocks Amid Medical Boom

ONC

Investor's Business Daily

2 months ago

Hims & Hers Leads 15 Growth Stocks Amid Medical Boom

BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL

ONC

Insider Monkey

2 months ago

BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order

ONC

Investor's Business Daily

2 months ago

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order

ONC

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Premarket Friday

ONC

MT Newswires

3 months ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Inflation Data

$BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)$

ONC

Business Wire

3 months ago

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

With 42% institutional ownership, BeOne Medicines Ltd. (NASDAQ:ONC) is a favorite amongst the big guns

ONC

Simply Wall St.

3 months ago

With 42% institutional ownership, BeOne Medicines Ltd. (NASDAQ:ONC) is a favorite amongst the big guns

BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025

ONC

Insider Monkey

3 months ago

BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

ONC

Business Wire

3 months ago

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

ONC

Business Wire

3 months ago

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

ONC

MT Newswires

3 months ago

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday

ONC

MT Newswires

3 months ago

Update: BeOne Medicines Sells Imdelltra Royalties to Royalty Pharma for Up to $950 Million

ONC

MT Newswires

3 months ago

BeOne Medicines Sells Imdelltra Royalties to Royalty Pharma for Up to $950 Million

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

ONC

Business Wire

3 months ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)

ONC

Simply Wall St.

3 months ago

BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

ONC

Business Wire

3 months ago

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth

ONC

Investor's Business Daily

3 months ago

This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

ONC

Investor's Business Daily

3 months ago

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

ONC

Business Wire

5 months ago

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

ONC

Business Wire

5 months ago

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

Exploring US High Growth Tech Stocks To Watch In June 2025

ONC

Simply Wall St.

5 months ago

Exploring US High Growth Tech Stocks To Watch In June 2025

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

ONC

Business Wire

5 months ago

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

ONC

Business Wire

5 months ago

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

ONC

Business Wire

5 months ago

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

BeOne Medicines And 2 Stocks That May Be Undervalued By The Market

ONC

Simply Wall St.

5 months ago

BeOne Medicines And 2 Stocks That May Be Undervalued By The Market

Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple

ONC

Investor's Business Daily

5 months ago

Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

ONC

Business Wire

5 months ago

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

ONC

Business Wire

6 months ago

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

ONC

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Premarket Tuesday

ONC

MT Newswires

6 months ago

Sector Update: Health Care

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

ONC

Business Wire

6 months ago

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

ONC

MT Newswires

6 months ago

BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

ONC

Business Wire

6 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

Exploring US High Growth Tech Stocks In May 2025

ONC

Simply Wall St.

6 months ago

Exploring US High Growth Tech Stocks In May 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

ONC

Business Wire

6 months ago

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

ONC

Simply Wall St.

6 months ago

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

ONC

Business Wire

6 months ago

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

ONC

Business Wire

6 months ago

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

ONC

The Wall Street Journal

6 months ago

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

ONC

Simply Wall St.

6 months ago

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ONC

Simply Wall St.

6 months ago

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

ONC

Insider Monkey

6 months ago

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

ONC

GuruFocus.com

6 months ago

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

ONC

MT Newswires

6 months ago

RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

ONC

Zacks

6 months ago

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

ONC

MT Newswires

6 months ago

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

ONC

MT Newswires

6 months ago

BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

ONC

Business Wire

6 months ago

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

ONC

Business Wire

7 months ago

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

3 Stocks That Could Be Trading Below Their Estimated Fair Value

ONC

Simply Wall St.

7 months ago

3 Stocks That Could Be Trading Below Their Estimated Fair Value

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

ONC

Investor's Business Daily

7 months ago

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

Exploring 3 High Growth Tech Stocks In The US Market

ONC

Simply Wall St.

7 months ago

Exploring 3 High Growth Tech Stocks In The US Market

BeiGene to Announce First Quarter 2025 Financial Results on May 7

ONC

Business Wire

7 months ago

BeiGene to Announce First Quarter 2025 Financial Results on May 7

ONC

MT Newswires

7 months ago

RBC Initiates BeiGene at Outperform With $312 Price Target

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

ONC

Simply Wall St.

7 months ago

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene halts ociperlimab amid poor Phase III trial predictions

ONC

Clinical Trials Arena

7 months ago

BeiGene halts ociperlimab amid poor Phase III trial predictions

ONC

MT Newswires

7 months ago

BeiGene to Discontinue Potential Lung Cancer Treatment Study

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

ONC

Business Wire

7 months ago

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

ONC

MT Newswires

8 months ago

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

ONC

Simply Wall St.

8 months ago

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

ONC

Business Wire

8 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

ONC

Simply Wall St.

8 months ago

Exploring 3 High Growth Tech Stocks In The US Market

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

ONC

Benzinga

8 months ago

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

ONC

MT Newswires

8 months ago

Beigene Insider Sold Shares Worth $2,073,826, According to a Recent SEC Filing

ONC

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Zymeworks Inc Earnings Call

ONC

MT Newswires

8 months ago

Beigene Insider Sold Shares Worth $24,674,638, According to a Recent SEC Filing

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

ONC

Simply Wall St.

8 months ago

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

ONC

Pharmaceutical Technology

8 months ago

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

ONC

MT Newswires

8 months ago

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

ONC

Business Wire

8 months ago

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

ONC

MT Newswires

8 months ago

Beigene Insider Sold Shares Worth $331,375, According to a Recent SEC Filing

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

ONC

Insider Monkey

9 months ago

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

ONC

Simply Wall St.

9 months ago

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

ONC

Insider Monkey

9 months ago

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

ONC

Simply Wall St.

9 months ago

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

ONC

Zacks

9 months ago

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

ONC

MT Newswires

9 months ago

Sector Update: Health Care Stocks Decline Premarket Thursday

ONC

MT Newswires

9 months ago

BeiGene Ltd BeiGene Q4 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Set

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

ONC

Business Wire

9 months ago

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

BeiGene to Present at Upcoming Investor Conferences

ONC

Business Wire

9 months ago

Latest BeiGene Ltd. American Depositary Shares (ONC) News on November 16, 2025

Share on Social Networks: